- Home
- PRQR
as of 07-16-2026 3:37pm EST
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
| Founded: | 2012 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 244.1M | IPO Year: | 2014 |
| Target Price: | $7.25 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $1.33 - $3.10 | Next Earning Date: | 05-07-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -16.39% | Revenue Growth (next year): | 13.92% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered PRQR Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of ProQR Therapeutics N.V. (PRQR)
Chief Executive Officer
Avg Cost/Share
$1.74
Shares
150,000
Total Value
$261,000.00
Owned After
300,000
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$1.59
Shares
150,000
Total Value
$238,500.00
Owned After
300,000
SEC Form 4
Director
Avg Cost/Share
$1.54
Shares
150,000
Total Value
$231,000.00
Owned After
150,000
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| de Boer Daniel Anton | PRQR | Chief Executive Officer | Jul 9, 2026 | Buy | $1.74 | 150,000 | $261,000.00 | 300,000 | |
| de Boer Daniel Anton | PRQR | Chief Executive Officer | Jul 7, 2026 | Buy | $1.59 | 150,000 | $238,500.00 | 300,000 | |
| Filius Bart | PRQR | Director | Jun 26, 2026 | Buy | $1.54 | 150,000 | $231,000.00 | 150,000 |
Compare PRQR vs Leading Stocks
See how PRQR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PRQR ProQR Therapeutics N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.